BCR::ABL1 transcripts and clinical outcome ‐ interrogating the technique

Branford, Susan

doi:10.1111/bjh.18046

Cited by 2 publications

(1 citation statement)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Other than biological differences, another possible explanation for the difference in the prognostic impact of the transcript types, especially in terms of molecular responses in the absence of a clear effect on survival, is correlated to technical issues. The real-time quantitative PCR (RT-qPCR) assays employed to measure BCR::ABL1 mRNA levels appear to be able to amplify the e13a2 amplicon more efficiently than the e14a2 amplicon [ 120 , 123 ]. This discrepancy in amplification performance may be related to the difference in amplicon length generated by the RT-qPCR assay (the e14a2 amplicon is approximately twice as large as e13a2), although the sequence itself may also be important [ 124 , 125 , 126 ].…”

Section: Baseline Prognostic Factorsmentioning

confidence: 99%

Prognosis in Chronic Myeloid Leukemia: Baseline Factors, Dynamic Risk Assessment and Novel Insights

Iezza

Cortesi

Ottaviani

et al. 2023

Cells

View full text Add to dashboard Cite

The introduction of tyrosine kinase inhibitors (TKIs) has changed the treatment paradigm of chronic myeloid leukemia (CML), leading to a dramatic improvement of the outcome of CML patients, who now have a nearly normal life expectancy and, in some selected cases, the possibility of aiming for the more ambitious goal of treatment-free remission (TFR). However, the minority of patients who fail treatment and progress from chronic phase (CP) to accelerated phase (AP) and blast phase (BP) still have a relatively poor prognosis. The identification of predictive elements enabling a prompt recognition of patients at higher risk of progression still remains among the priorities in the field of CML management. Currently, the baseline risk is assessed using simple clinical and hematologic parameters, other than evaluating the presence of additional chromosomal abnormalities (ACAs), especially those at “high-risk”. Beyond the onset, a re-evaluation of the risk status is mandatory, monitoring the response to TKI treatment. Moreover, novel critical insights are emerging into the role of genomic factors, present at diagnosis or evolving on therapy. This review presents the current knowledge regarding prognostic factors in CML and their potential role for an improved risk classification and a subsequent enhancement of therapeutic decisions and disease management.

show abstract